IMMX (Immix Biopharma) Total Liabilities: $10.19 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMMX Immix Biopharma Inc IMMX
22 GF Score
Price $13.67
! 2 Warning Signs
View Full Analysis

What is Immix Biopharma Total Liabilities?

Immix Biopharma IMMX +3.80% 22 Total Liabilities is $10.19 Mil as of Jun. 2026. GuruFocus rates IMMX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

Immix Biopharma's Total Liabilities for the quarter that ended in Jun. 2026 was $10.19 Mil.

Immix Biopharma's quarterly Total Liabilities increased from Dec. 2025 ($11.04 Mil) to Mar. 2026 ($11.45 Mil) but then declined from Mar. 2026 ($11.45 Mil) to Jun. 2026 ($10.19 Mil).

Immix Biopharma's annual Total Liabilities increased from Dec. 2023 ($3.72 Mil) to Dec. 2024 ($9.70 Mil) and increased from Dec. 2024 ($9.70 Mil) to Dec. 2025 ($11.04 Mil).

Immix Biopharma Total Liabilities Historical Data

* Premium members only.

The historical data trend for Immix Biopharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immix Biopharma Total Liabilities Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 0.20 1.75 3.72 9.70 11.04

Immix Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.98 11.82 11.04 11.45 10.19
IMMX
22GF Score
Immix Biopharma Inc IMMX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immix Biopharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Immix Biopharma's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.111+(0.934+-0.0010000000000002
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=11.04

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=104.84-93.796
=11.04

Immix Biopharma's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.302+(0.891+-0.00099999999999945
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=10.19

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=239.109-228.917
=10.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $10.19 Mil mean?
Immix Biopharma (IMMX) has a Total Liabilities of $10.19 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Immix Biopharma and its competitors.
Is Immix Biopharma's Total Liabilities too high?
Immix Biopharma's current Total Liabilities is $10.19 Mil. Overall, Immix Biopharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Immix Biopharma's Total Liabilities compare to CBIO and NVCT?
Immix Biopharma's Total Liabilities of $10.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Immix Biopharma and its competitors. Immix Biopharma's current Total Liabilities is $10.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immix Biopharma stock overvalued right now?
Immix Biopharma (IMMX) has a current Total Liabilities of $10.19 Mil. The current Total Liabilities is $10.19 Mil. Immix Biopharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Immix Biopharma (IMMX), the current Total Liabilities is $10.19 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immix Biopharma Business Description

Address 11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
22GF Score

Get the complete analysis for IMMX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.67
Price